Dose-response relationship in the treatment of idiopathic thrombocytopenic purpura with intravenous immunoglobulin.
The dose-response relationship in the intravenous immunoglobulin treatment of idiopathic thrombocytopenic purpura was studied in 20 adult patients in a multicenter prospective crossover trial. The rate of response increases from 3 out of 11 (27%) to 6 out of 10 treatment periods (60%) by raising the 7S-IgG dose given on 5 consecutive days from 164.50 +/- 24.55 to 359.65 +/- 58.62 mg/kg body weight. The onset and duration of response as well as the peak platelet count were found to be independent of the doses. A long-term benefit induced by intravenous immunoglobulin treatment could be achieved in 2 out of 14 patients with chronic idiopathic thrombocytopenic purpura.
Emmerich
B
B
Hiller
E
E
Woitinas
F
F
Maubach
P A
PA
Riess
H
H
Nerl
C
C
Geursen
R G
RG
D000293:Adolescent; D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D010976:Platelet Count / Q000187:drug effects; D011696:Purpura, Thrombocytopenic / Q000628:therapy*
D007074:Immunoglobulin G